Infusystem Holdings, Inc (INFU) Stock Price & Analysis
Infusystem Holdings, Inc (INFU) rose 2.59% to USD 9.12 as of July 25, 2026 at 05:57 UTC, according to Nexqual real-time market data.
INFU last closed at USD 8.89; the session ranged USD 8.99–9.26 on volume of 96,846 shares. Market capitalization is $184.06M, with a 52-week range of USD 5.43–11.04 (ASE). Source: Nexqual, July 25, 2026 at 05:57 UTC.
Key Statistics (as of July 25, 2026 at 05:57 UTC)
| Price | USD 9.12 |
|---|---|
| Change | ▲ 2.59% (up) |
| Previous Close | USD 8.89 |
| Open | USD 8.89 |
| Day Range | USD 8.99 – 9.26 |
| 52-Week Range | USD 5.43 – 11.04 |
| Volume | 96,846 shares |
| Market Cap | $184.06M |
| Exchange | ASE |
Technical Analysis (INFU)
Nexqual's technical model rates INFU "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:57 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.66 (neutral) |
| vs SMA50 | Below (USD 9.25) |
| MACD | -0.11 (negative) |
Analyst Ratings (INFU)
Wall Street analysts rate INFU "None" based on 4 analysts, with a mean price target of USD 14.88 (range USD 12–17.5), per Nexqual as of July 25, 2026 at 05:57 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 14.88 |
| High Target | USD 17.5 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (INFU)
| Next Earnings Date | 2026-08-04 |
|---|---|
| Revenue Estimate | $36.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.05 vs est 0.03 ▲ beat |
| 2025-12-31 | USD 0.1 vs est 0.07 ▲ beat |
| 2025-09-30 | USD 0.15 vs est 0.05 ▲ beat |
| 2025-06-30 | USD 0.15 vs est 0.04 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:57 UTC.
Financials & Fundamentals (INFU)
| Total Revenue | $142.40M |
|---|---|
| Revenue Growth (YoY) | -3.00% |
| Gross Margin | +56.75% |
| Operating Margin | +4.72% |
| Profit Margin | +5.55% |
| ROE | +13.89% |
| Debt / Equity | 41.03 |
| Current Ratio | 2.14 |
| Total Cash | $2.11M |
| Total Debt | $24.10M |
| Free Cash Flow | $17.43M |
Source: Nexqual, July 25, 2026 at 05:57 UTC.
Financial Health Score (INFU)
Nexqual rates Infusystem Holdings, Inc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 05:57 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 57%, operating 5% |
| Balance Sheet | Strong — $2M cash vs $24M debt |
| Cash Flow | Solid — FCF $17M, 12% margin |
| Efficiency | Mixed — ROE 14%, ROA 6.7% |
Ownership (INFU)
| Insider Ownership | +7.15% |
|---|---|
| Institutional Ownership | +79.81% |
| Shares Outstanding | 20.18M |
| Float | 18.71M |
| Short % of Float | +4.22% |
Source: Nexqual, July 25, 2026 at 05:57 UTC.
Leadership (INFU)
Infusystem Holdings, Inc is led by Carrie A. Lachance B.S.N., M.B.A., R.N. (age 48), President, CEO & Director, per Nexqual as of July 25, 2026 at 05:57 UTC.
| President, CEO & Director | Carrie A. Lachance B.S.N., M.B.A., R.N. (age 48) |
|---|---|
| Executive VP & CFO | Barry G. Steele (age 54) |
Major Backers & Investors (INFU)
Notable institutional backers of Infusystem Holdings, Inc include First Eagle Investment Management, LLC, Minerva Advisors LLC, American Century Companies Inc, according to Nexqual as of July 25, 2026 at 05:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Investment Management, LLC | 6.73% |
| Minerva Advisors LLC | 5.97% |
| American Century Companies Inc | 5.34% |
| Punch & Associates Investment Management, Inc. | 4.15% |
| Acadian Asset Management. LLC | 3.14% |
| Renaissance Technologies | 2.81% |
| Heartland Advisors Inc. | 2.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.4% |
| BlackRock | 3.06% |
| Dimensional Fund Advisors | 2.94% |
Source: Nexqual, July 25, 2026 at 05:57 UTC.
From Infusystem Holdings, Inc's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada.
- It operates through two segments: Patient Services and Device Solutions.
- The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
- It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELMD | Electromed, Inc. | USD 38.41 | ▼ 2.81% |
| IRIX | IRIDEX Corporation | USD 0.89 | ▼ 3.15% |
| JYNT | The Joint Corp. | USD 8.35 | ▼ 3.24% |
| MLSS | Milestone Scientific, Inc. | USD 0.39 | ▼ 9.3% |
| KRMD | KORU Medical Systems, Inc. | USD 3.83 | ▼ 0.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:57 UTC. This page is informational and not investment advice.